Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, Verma A, Neugebauer KM, Pillai MM. Boddu PC, et al. Among authors: chandhok ns. Mol Cell. 2024 Apr 18;84(8):1475-1495.e18. doi: 10.1016/j.molcel.2024.02.032. Epub 2024 Mar 22. Mol Cell. 2024. PMID: 38521065
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Kim TK, Han X, Hu Q, Vandsemb EN, Fielder CM, Hong J, Kim KW, Mason EF, Plowman RS, Wang J, Wang Q, Zhang JP, Badri T, Sanmamed MF, Zheng L, Zhang T, Alawa J, Lee SW, Zeidan AM, Halene S, Pillai MM, Chandhok NS, Lu J, Xu ML, Gore SD, Chen L. Kim TK, et al. Among authors: chandhok ns. J Clin Invest. 2024 Feb 1;134(3):e164325. doi: 10.1172/JCI164325. J Clin Invest. 2024. PMID: 38060328 Free PMC article.
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
Bewersdorf JP, Stahl M, Taylor J, Mi X, Chandhok NS, Watts J, Derkach A, Wysocki M, Lu SX, Bourcier J, Hogg SJ, Rahman J, Chaudhry S, Totiger TM, Abdel-Wahab O, Stein EM. Bewersdorf JP, et al. Among authors: chandhok ns. Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9. Leukemia. 2023. PMID: 37814121 Free PMC article. Clinical Trial. No abstract available.
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. Gbyli R, et al. Among authors: chandhok ns. Leukemia. 2022 May;36(5):1313-1323. doi: 10.1038/s41375-022-01536-x. Epub 2022 Mar 10. Leukemia. 2022. PMID: 35273342 Free PMC article.
15 results